2.31 USD
↘ 0.04 (1.70%)AT CLOSE (11:59 AM EDT)
Allogene Therapeutics, Inc. Common Stock
ALLONASDAQ • USD
2.30
↘ 0.02 (0.65%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
2.30
↘ 0.02 (0.65%)
Market: CLOSED
Open?$2.33
High?$2.38
Low?$2.26
Prev. Close?$2.35
Volume?5.5M
Avg. Volume?13.6M
VWAP?$2.32
Rel. Volume?0.41x
Bid / Ask
Bid?$1.96 × 100
Ask?$2.63 × 100
Spread?$0.67
Midpoint?$2.30
Valuation & Ratios
Market Cap?794.6M
Shares Out?244.8M
Float?150.9M
Float %?67.1%
P/E Ratio?N/A
P/B Ratio?2.72
EPS?-$0.55
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?7.93Strong
Quick Ratio?7.93Strong
Cash Ratio?1.59Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?N/A▾
P/B?2.72CHEAP▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.8CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-65.3%WEAK▾
ROA?-45.9%WEAK▾
Cash Flow & Enterprise
FCF?$-149632000
Enterprise Value?$742.9M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Employees
152
Market Cap
794.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-11
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700